All the components of early goal-directed therapy, especially central venous oxygen saturation (ScvO 2 ) as one of the endpoints of resuscitation, may not have mortality benefit, more so after results of the Australasian Resuscitation of Sepsis Evaluation, A Randomized Trial of Protocol-Based Care for Early Septic Shock, and The Protocolised Management in Sepsis trials. However, extrapolating results from trials undertaken in the developed world may not be entirely appropriate.
INTRODUCTION
Sepsis is among the most common causes of mortality and morbidity in emergency medical services. Mortality due to sepsis continues to remain high in the range of 10-60% despite great advances in medicine. [1] [2] [3] [4] [5] [6] The search for a specific management protocol for the complicated problem of severe sepsis and septic shock started with the Rivers' study in 2001, which introduced the early goal-directed therapy (EGDT). EGDT produced a significant reduction in mortality in patients with severe sepsis and septic shock. The EGDT, thus, introduced a new hemodynamic parameter: central venous oxygen saturation (ScvO 2 ). [7] As the central line was an essential part of the EGDT, to measure central venous pressure (CVP), ScvO 2 was easy to measure in all patients. Because ScvO 2 is the oxygen saturation of venous blood returning to the heart, it represents the balance of systemic oxygen delivery and oxygen consumption by tissue. A low ScvO 2 reflects either decreased oxygen delivery or increased oxygen extraction or both. A normal ScvO 2 means that the body is able to compensate for the increased oxygen demand by increasing the cardiac output and the respiratory rate. A high ScvO 2 reflects either oxygen delivery above demand or decreased oxygen extraction due to blockage in the capillaries (microclotting in sepsis) or mitochondrial dysfunction.
Three recently published large randomized studies, including Australasian Resuscitation of Sepsis Evaluation (ARISE), A Randomized Trial of Protocol-Based Care for Early Septic Shock (ProCESS), and The Protocolised Management in Sepsis (PROMISE) trial, have challenged the benefit of EGDT approach in improving survival in severe sepsis and septic shock and suggest that some interventions carried out during EGDT algorithm may not have mortality benefit (central venous catheter [CVC] insertion, ScvO 2 monitoring, dobutamine, and transfusion triggers for hematocrit <30%). [8] [9] [10] These findings have brought in focus the utility of targeting a predefined value of ScvO 2 in the management of severe sepsis/septic shock. However, there is an important caveat in interpreting the result of these trials as there is a significant difference in the mean baseline ScvO 2 value in patients recruited in Rivers' trial as compared to patients recruited in these three trials. The mean initial ScvO 2 reported by Rivers et al. was 49%, which is lower than that documented at baseline in these trials. [7] [8] [9] [10] Extrapolating results from these trials undertaken in the developed world would not be entirely appropriate. It would therefore be pertinent to find out the mean baseline ScvO 2 , the prevalence of abnormal ScvO 2 , both low and high at presentation, and their prognostic significance in a cohort of patients presenting with severe sepsis/septic shock in our emergency medical services in developing world.
MATERIALS AND METHODS
This single-center prospective observational study was conducted in the emergency medical services of a tertiary care institution in North-Western India. Two hundred adult (≥18 years old) medical patients admitted to the emergency medical services for more than 24 h with an admission diagnosis of severe sepsis and/or septic shock fulfilling all inclusion and exclusion criteria were included in the study. [11] Exclusion criteria were patients <18 years old, pregnant females, patients with primary admitting diagnosis of acute pulmonary edema, acute myocardial infarction, cerebrovascular event, asthma exacerbation, major cardiac arrhythmia, seizure, drug overdose, injury from burn or trauma, active gastrointestinal hemorrhage leading to hemodynamic instability, requirement for immediate surgery, do-not-attempt-resuscitation status, contraindication to central venous catheterization, contraindication to blood transfusion and transferred from another in-hospital setting with duration of stay of more than 24 h. Sociodemographic details, baseline clinical and laboratory parameters were recorded in a predesigned instrument. Arterial blood gas (Model: Cobas b 121, Manufacturer: Roche) was measured at presentation and as and when required from the peripheral artery and central venous line. Line insertion involved a CVC, inserted either into subclavian or internal jugular vein. The CVC was inserted using standard techniques for central access. Guidelines of the CVC care bundle were followed for insertion and day to day care. A blood sample was taken as soon as possible after CVC insertion from the superior vena cava through the CVC for the measurement of ScvO 2 by a standard blood gas analyzer. The ScvO 2 levels were stratified into three groups of hypoxia (ScvO 2 0-69%), normoxia (ScvO 2 70-89%), and hyperoxia (ScvO 2 90-100%). [12] These thresholds have been selected a priori. The severity of illness was assessed by sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation (APACHE II) score from the data collected during the first 24 h following admission. All patients were followed up throughout their hospital stay, and requirement of any kind of organ support, e.g., renal replacement therapy, mechanical ventilation, and the vasoactive agents were also recorded in a predesigned proforma. The immediate cause of death in the case of hospital mortality was noted. The institute ethics committee approved the study. Informed consent was obtained from the patient or next of kin. We have scrupulously followed all the checklists contained in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline during reporting the index study.
Statistical analyses
The data were expressed as percentages (%), mean ± SD, or median and 25% to 75% interquartile range (IQR), as appropriate. Patients were divided into hospital survivors and nonsurvivors; also based on ScvO 2 levels at baseline, patients were stratified into three groups: hypoxia (ScvO 2 0-69%), normoxia (ScvO 2 70-89%), and hyperoxia (ScvO 2 90-100%). Between groups of survivors and nonsurvivors, continuous and categorical characteristics were analyzed. Continuous, normally distributed variables were compared with the t-test, and for nonnormally distributed, Mann-Whitney U-test was used. Categorical variables were compared utilizing the Chi-square test. To determine the univariate relationship between hypoxia, hyperoxia, and normoxia groups, categorical variables between these groups were compared using the Chi-square test. For normally distributed continuous variables between these three groups, the analysis of variance test was used. For nonnormally distributed continuous variables, Kruskal-Wallis test was used. For further characterization of significant P values found on the Kruskal-Wallis test, Mann-Whitney test was applied taking two out of three groups in different combinations. We also carried out multivariate logistic regression analysis to find out variables independently associated with hospital mortality. Variables with P < 0.1 on univariate analysis were included in multivariate logistic regression analysis. Statistical analysis was performed using the statistical software SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). All tests were two-tailed. P < 0.05 was considered statistically significant.
RESULTS AND OBSERVATIONS
In this single-center prospective observational study, we analyzed 200 patients with severe sepsis and septic shock admitted in the emergency medical services attached to the department of internal medicine in the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, a tertiary care institution in North-West India. The mean age of patients was 46.7 ± 17.6 years. The male preponderance (114 [57%]) was noted. Hypertension was the most common comorbidity noted in 61 (30.5%) patients. The most common identifiable source of infection at presentation was pulmonary system infections in 78 (39%) patients. Based on initial ScvO 2 data, out of 200 patients, 104 (52%) patients had a low ScvO 2 level, also leveled as the hypoxic group. Sixty-five (32.5%) patients had an initial ScvO 2 level in between 70 and 89%, a priori classified as the normoxic group, and the remaining 31 (15.5%) patients had high ScvO 2 , leveled as the hyperoxic group. The mean ScvO 2 of study cohort at baseline was 65.9 ±20.7%. The mean SOFA score of study cohort at hospital admission was 9.7 ± 3.7, whereas the mean APACHE II score was 24.8 ± 7.1. The mean APACHE II score of the hypoxic group was 24.7 ± 6.9, of the normoxic group was 24.7 ± 7.5, and of the hyperoxic group was 25.1 ± 7.1. Similarly, the mean SOFA score of the hypoxic group was 9.9 ± 3.7, of the normoxic group was 9.6 ± 3.7, and of the hyperoxic group was 10.0 ± 3.9. The median lactate level at baseline was 2.98 mmol/l (IQR = 2.05-4.42). The median lactate levels in the hypoxia, normoxia, and hyperoxia groups were 3.10 (2.30-4.41), 2.65 (2.00-5.30), and 2.92 (2.00-4.06) mmol/l, respectively. Of the 200 patients with severe sepsis and septic shock, acute renal failure was noted in 179 (89.5%) patients, acute respiratory failure in 146 (73%), acute cardiovascular failure in 121 (60.5%), central nervous system failure in 106 (53%) patients, and gastrointestinal failure in 98 (49.5%) patients. Inotrope usage was documented in 123 (61.5%) patients. The median duration of inotrope use was 50.00 (IQR -30.00-96.00) hours. The refractory septic shock was documented in 50 (25%) patients. Eighty-eight (44%) patients required invasive mechanical ventilation. The median duration of mechanical ventilation was 3.00 (2.00-8.00) days. Forty-seven (23.5%) patients required renal replacement therapy, of which 35 were diagnosed cases of chronic kidney disease (CKD). The median duration of hospital stay was 9.00 (IQR -4-14) days. The median duration of hospital stay was 9.00 (5.00-14.00) days for hypoxia group, 9.00 (5.00-13.50) days for normoxia group, and 8.00 (3.00-18.00) days for hyperoxia group. Sixty-six (33%) patients had hospital mortality. Further details of various parameters of the whole study cohort are summarized in Tables 1 and 2. Various sociodemographic, clinical, and laboratory parameters; the severity of illness scores; and hospital outcome variables were compared between nonsurvivors and survivors. APACHE II score at admission was significantly higher in nonsurvivors as compared to survivors ([27.58 ± 7.56 vs. 23.38 ± 6.41], P ≤ 0.001). SOFA score at admission was also significantly higher in nonsurvivors as compared to survivors ([11.82 ± 2.80 vs. 8.68 ± 3.62], P ≤ 0.001). The mean serum lactate level at baseline was significantly higher in nonsurvivors ([4.84 ± 3.37 vs. 3.16 ± 1.83 mmol/l], P ≤ 0.001) as well. Nonsurvivors had significantly higher incidence of cardiovascular ([86.40% vs. 47.80%], P ≤ 0.001) and central nervous system failure ([77.30% vs. 41.00%], P ≤ 0.001). The incidence of refractory septic shock was also significantly higher in the nonsurvivor group. The mean values of ScvO 2 at baseline were also compared among survivors and nonsurvivors, but the differences were not statistically significant. Further elaboration of univariate analysis of various sociodemographic, clinical, laboratory, organ failure assessment, and hospital outcome parameters among survivors and nonsurvivors is shown in Tables 3 and 4 . We also carried out multivariate logistic regression analysis to find out the variables independently associated with hospital mortality. Age, serum lactate, and SOFA score at baseline were found to be independently associated with hospital mortality [ Table 5 ].
We similarly compared various sociodemographic, clinical, laboratory, the severity of illness scores, and hospital outcome variables among groups with hypoxia, hyperoxia, and normoxia categorized based on baseline ScvO 2 . We found no significant difference in APACHE II, SOFA score, and hospital mortality among the three groups on univariate analysis. The details are provided in Tables 6 and 7 The mean age of patients recruited in the study cohort was 46.70 ± 17.64 years, much lower than population recruited in three large randomized trials -ARISE, PROCESS, and PROMISE. [8] [9] [10] In Rivers' trial, as well, the median age of the recruited study cohort was 66 years. [7] The mean SOFA score of study cohort at hospital admission was 9.71 ± 3.68, whereas the mean APACHE II score was 24.77 ± 7.06 in the index study. In Rivers' trial, APACHE II at enrolment in the EGDT group was 21.4 ± 6.90 and in the control group was 20.4 ± 7.4. [7] APACHE II score in PROCESS trial in the EGDT group was 20.8 ± 8.1, in protocol-based therapy was 20.6 ± 7.4, and in usual care group was 20.6 ± 7.4. [8] In ARISE severity of illness score, APACHE II was 15.4 in the EGDT group, whereas it was 15.8 in the control group. [9] Analyzing these data, it is evident that in our index study, patients enrolled had a much higher severity of illness at presentation, even higher than patients recruited in the Rivers' trial. Possible reasons could be the tertiary care referral nature of our institute, type of illnesses, socioeconomic milieu of the patient population, and late presentation.
One of the main objectives of our study was to find out the mean ScvO 2 and prevalence of abnormal ScvO 2 at presentation. We found that the mean ScvO 2 at the presentation of the whole cohort was 65.95 ± 20.7%. In a seminal study, Rivers et al. introduced the EGDT concept to which we alluded to previously. In this study, the mean ScvO 2 of the group receiving standard therapy was 49.2 ± 13.3% at baseline, whereas for EGDT group, it was 48.6 ± 11.2%. At the end of 6 h, the mean ScvO 2 was still below the 70% mark at 66.0 ± 15.5% in the control group. The group receiving EGDT showed marked improvement in ScvO 2 at the end of the 6-h bundle; it was 77.3 ± 10.0% (P < 0.001). The main difference between standard therapy and EGDT in this trial was a time-bound achievement of resuscitation endpoints, especially the ScvO 2 level of >70%. [7] However, as time progressed, clinicians started questioning the importance of each element of EGDT. To answer these questions, three large RCTs, PROMISE, PROCESS, and ARISE, were conceptualized and undertaken in various parts of , inotropes infusion, and blood transfusions to maintain hematocrit >30%) might not have morbidity and mortality benefit. However, on closer analysis of data of these trials, we find that in all of them, baseline ScvO 2 was more than 70% (71% in PROCESS, 72.7% in ARISE, and 70.1% in PROMISE trial). [8] [9] [10] Our index study showed lower ScvO 2 as compared to these studies at baseline. As one of the important resuscitation endpoints in previous surviving sepsis campaign (SSC) guidelines was the attainment of ScvO 2 to more than 70% by various interventions; however, importantly in these three RCTs, the baseline ScvO 2 was more than 70%, the desired level recommended in SSC guidelines. Furthermore, on critically analyzing these trial data, we find that SOFA and APACHE II scores were much lower and the mean lactate levels were also lower as compared to Rivers' trial and our index study. It can, therefore, be inferred that patients recruited in all three trials were less sick and probably they were recruited at the earlier phase of their septic illness as compared to patients recruited in Rivers' and our index study. Therefore, extrapolating the data of these trials done primarily in the developed world in sepsis patients with lesser severity of illness would be tad premature. We suggest that multicentric trials on similar lines should be undertaken in the developing world as well before abandoning ScvO 2 measurement and its optimization in managing such patients.
In the index study, the prevalence of hypoxia at presentation in terms of baseline ScvO 2 was 52% (104/200). Normoxia was documented in 32.50% (65/200) and hyperoxia in 15.50% (31/200) of patients. The hospital mortality was 26.92% (28/104) in the hypoxic group. It is quite evident that nonsurvivors continued to have lower ScvO 2 levels even after 6 h of protocolized endpoint-guided interventions, whereas survivors had shown marked improvement in ScvO 2 level after 6 h of resuscitative efforts. Hypoxia or low ScvO 2 in these sepsis/septic shock patients is most likely due to macrocirculatory failure. In a prospective multicenter observational study, 363 patients with septic shock admitted in intensive care units (ICUs) were analyzed. One hundred and eleven patients had low initial ScvO 2 . 28-day mortality was significantly higher in patients with low ScvO 2 as compared to the group with initial ScvO 2 ≥70% (37.8% vs. 27.4%). [13] In another observational study, it was found that patients with ScvO 2 <60% at baseline during ICU admission was associated with increased mortality. [14] A hyperoxic group is an intriguing group of patients. High ScvO 2 could be simply due to the delivery of oxygen, which is more than tissue requirements. However, more worryingly, it could be an indicator of decreased cellular consumption of oxygen either due to microcirculatory or mitochondrial failure. Hospital mortality should have been much lower if it was secondary to just the higher delivery of oxygen, which is more than what is required at the cellular level for various metabolic processes, and serum lactate in this scenario should have been lower or normal. Hospital mortality in the hyperoxic group was 41.93% (13/31) in the index study. Interestingly, the mean serum lactate value at baseline was much higher (4.52 ± 2.95 mmol/l) in the group of patients who had hospital mortality as compared to survivors (2.89 ± 1.55 mmol/l) in this hyperoxic group. These findings are indicative of either microcirculatory or mitochondrial dysfunction in this group of patients with hyperoxia. Markers of the severity of illness and organ dysfunction, both APACHE II and SOFA score, were significantly higher in nonsurvivors as compared to survivors, indicating greater severity of illness among them. All these parameters indicate that in this group especially in patients who had hospital mortality, many patients had either a microcirculatory This study aimed to find out whether abnormal (both low and high) ScvO 2 is associated with increased mortality. Hospital mortality was highest in the group of patients with hyperoxia (31%). [12] In a study undertaken by Textoris et al., a retrospective analysis of 152 patients of septic shock admitted in ICU was done to find out the relation between maximal ScvO 2 levels (ScvO 2 max) and survival. The mortality rate in a group of patients with ScvO 2 max <80% was 30%, and in patients with ScvO 2 over 80%, the mortality rate was 48%. [15] The association between maximum ScvO 2 and mortality persisted in a multivariate analysis adjusted for other variables. Patients with hyperoxia based on ScvO 2 value are thus an important subset of patients, who require closer scrutiny. The microcirculation and mitochondrial function should be monitored in real-time with devices such as orthogonal polarization spectral imaging, sidestream dark-field imaging, and near-infrared spectroscopy. Prognostic importance of hyperoxia provides a possible avenue for future research in this field to find a therapeutic target. Possible therapies which could be researched might be a unique form of resuscitative interventions to normalize microcirculatory flow in real-time using video microscopy and using novel therapies to recruit microcirculatory blood flow. Another therapeutic target could be mitochondrial activity and improve the same by use of novel factors.
Our study has many strengths. It was a prospective observational study of patients with a confirmed diagnosis of severe sepsis and septic shock. All patients were managed under similar settings with a uniform institutional management protocol based on SSC guidelines. We included patients having a wide range of comorbidities and a variety of illnesses.
However, the present study also had certain limitations.
As it is a single-center study, conducted in a tertiary care institution, the results may not be generalizable to other health-care institutions. This study included 200 patients, a sample size which may not seem as robust as earlier studies. The index study included only patients admitted to emergency medical services, and hence the results may not be extrapolated to surgical patients with severe sepsis/septic shock. As patient recruitment was not consecutive, the possibility of selection bias might have been introduced. ScvO 2 was not measured continuously, which might have led to ascertainment bias as we might have missed abnormal ScvO 2 values.
